Conference Day One: Tuesday, March 19, 2024

8:00 am Registration Open & Coffee Networking

8:30 am Chair’s Opening Remarks

8:45 am Exploring the Current NK Landscape

Synopsis

Download the full event guide to find out more on session details

9:30 am Keynote Panel Discussion: Reigniting Pharma & Investor Interest in NK Cell Therapies

Synopsis

Download the full event guide to find out more on session details

10:00 am Lead Partner Presentation: Miltenyi Biotec

10:30 am Morning Refreshments & Speed Networking

Preclinical

Transforming Cell Engineering for Functional Advancements

11:30 am AlloNK® as an ADCC Enhancer

  • Heather Raymon Senior Vice President, Research & Early Development, Artiva Biotherapeutics, Inc

Synopsis

Download the full event guide to find out more on session details

11:30 am Modifying NK cells through Genetic Engineering to Enhance Their Persistence and Functionality

12:00 pm Engineering NK Cells for Combinational Therapies

  • Seung-Hwan Lee Professor, Department of Biochemistry, Microbiology, and Immunology, University of Ottawa

Synopsis

Download the full event guide to find out more on session details

12:00 pm Engineering CAR constructs for NK Cells

12:30 pm Audience Led Discussion: NK Engagers vs NK Cell Therapies

Synopsis

Download the full event guide to find out more on session details

Clinical Translation

Streamlining Clinical Trial Design for Improved Targeting of the TME & Overall Faster Phase Development Success

11:30 am The Unique Challenges of Translating ProtoNK Therapies into Clinical Success

  • Allen Feng Founder & Chief Scientific Officer, HebeCell

Synopsis

Download the full event guide to find out more on session details

12:00 pm A Sanofi Case Study: Designing a Robust Clinical Design & Evaluation Strategy to Enter the Clinic

  • Sarah Cooley Senior Global Project Head-Hematologic Oncology, Sanofi

Synopsis

Download the full event guide to find out more on session details

12:30 pm Audience Led Discussion: Overcoming Unique Challenges of Clinical Trial Designs for Streamlined Entry into the Clinic

CMC & Process Development

Ensuring Safety and Efficiency in Gold Standard Manufacturing Practices

11:30 am Bringing A MAGE-A4 Targeting “Off the Shelf” TCR-NK Cells Into the Clinic: Leveraging Pre-Clinical And Manufacturing Interplay

  • Emilie Gauthy Head of Chemistry, Manufacturing & Controls, Zelluna Immunotherapy

Synopsis

Download the full event guide to find out more on session details

12:00 pm Pooled Donor Manufacturing for Highly Scalable Generation of Potent NK Cells

  • Colleen Delaney Scientific Founder, Chief Scientific Officer and Executive VP of R&D, Deverra Therapeutics

Synopsis

Download the full event guide to find out more on session details

12:30 pm Program Partner Presentation by Militenyi Biotec

Synopsis

Download the full event guide to find out more on session details

1:00 pm Lunch & Networking

Understanding Novel Technologies within NK Cells to Produce of “Well-Behaving” NK cells

2:00 pm Novel Technologies to Produce Highly Cytotoxic NK Cells Using CD34+ Cord Blood Cells

  • Hugh Brady Professor - Immunology, Imperial College London

Synopsis

Download the full event guide to find out more on session details

2:30 pm Building Polyvalent NK Cell Engagers for Enhanced Tumor Targeting and Therapeutic Efficacy

  • Xavier Michelet Director, Senior Investigator, Head of Pharmacology & Biology, AI Proteins

Synopsis

Download the full event guide to find out more on session details

Streamlining Clinical Trial Design for Improved Targeting of the TME & Overall Faster Phase Development Success

2:00 pm Engineered NK-92 (aNKTM) Cells – Preclinical & Clinical Results

  • Hans Klingemann Vice President - Research & Development, ImmunityBio, Inc.

Synopsis

Download the full event guide to find out more on session details

2:30 pm Gene Editing Strategies to Enhance CAR-NK Cell Function in The Solid Tumor Microenvironment

Synopsis

Download the full event guide to find out more on session details

Elevating Live Cell Manufacturing Efficiency and Quality Through Feeder & Non-Feeder Cell Technologies

2:00 pm Investigating the Benefits of Feeder-Free NK Cell Expansion

  • Adil Duru Director of Business Development, Glycostem

Synopsis

Download the full event guide to find out more on session details

2:30 pm Expanding Cytokine Induced Memory Like (CIML) NK Cells Using Feeder Cell Technology

  • Yansen Xiao Postdoctoral Fellow, University of Pennsylvania

Synopsis

Download the full event guide to find out more on session details

3:00 pm Afternoon Refreshments & Poster Session

4:00 pm Roundtable: Engineering Well Behaving NK Cells for Enhanced Therapeutic Efficacy

  • Xi Shi Director, Takeda Pharmaceutical Co. Ltd.

Synopsis

Download the full event guide to find out more on session details

4:30 pm An Update on Immune Bridge’s Non-Engineered NK Cell Therapy

  • Jesse Cotari Co-founder & Chief Scientific Officer, ImmuneBridge

Synopsis

Download the full event guide to find out more on session details

4:00 pm Fireside chat: Bispecific Antibodies and AI Machine Learning

  • Tony Arulanandam SVP and Head of Preclinical Research and Development, Cytovia Therapeutics
  • Armin Rath Chief Operating Officer, Cytovia Therapeutics

Synopsis

Download the full event guide to find out more on session details

4:30 pm Cytovia Therapeutics Presents New Data on CD38 & CD30 NK Cells

  • Tony Arulanandam SVP and Head of Preclinical Research and Development, Cytovia Therapeutics

Synopsis

Download the full event guide to find out more on session details

4:00 pm Roundtable: Optimizing Expansion Strategies for Enhanced Therapeutic Impact

  • Yu Qian Associate Director - CMC, & Cell Therapies, Takeda Pharmaceutical Co. Ltd.

Synopsis

Download the full event guide to find out more on session details

4:30 pm An Introduction into Mendus’s NK Cell Platform

Synopsis

Download the full event guide to find out more on session details

5:00 pm Chair’s Closing Remarks

5:10 pm Drinks Reception

Close of Day 1